Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | XIAP | P98170 | 4/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713671 | 1.00 | RORC (0.35) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL1613453 | 1.00 | RORC (0.35) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL1612498 | 0.85 | RORC (0.36) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL1612501 | 0.85 | RORC (0.36) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL1612502 | 0.85 | RORC (0.36) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL12713649 | 0.85 | RORC (0.36) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL1612202 | 0.85 | RORC (0.38) | RORCXIAPBIRC2KDM1AUSP30 | |
| SCHEMBL12713647 | 0.85 | RORC (0.38) | RORCXIAPBIRC2KDM1AUSP30 | |
| SCHEMBL1614018 | 0.77 | XIAP (0.41) | RORCXIAPBIRC2KDM1ACASP1 | |
| SCHEMBL19583492 | 0.77 | XIAP (0.41) | RORCXIAPBIRC2KDM1ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | RORC 301/4885XIAP 539/4885BIRC2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.